BioCentury | Sep 30, 2020
Politics, Policy & Law

Former FDA leaders call out White House for undermining FDA

...hydroxychloroquine and convalescent plasma, and an Axios-Ipsos poll...
BioCentury | Sep 16, 2020
Politics, Policy & Law

Vaccine hesitancy: why American values matter

More than a third of Americans tell polls they would not take a vaccine to prevent COVID-19, the most devastating disease in 100 years. Vaccine hesitancy is even higher among Black people — hard-hit in...
BioCentury | Sep 11, 2020
Product Development

COVID-19 should spur massive investment in science and technology, Regeneron’s Yancopoulos says: a BioCentury audio interview

In addition to preparing for future pandemics, the U.S. should increase its investments in science and technology by orders of magnitude to head off crippling onslaughts of disease, Regeneron’s George Yancopoulos told BioCentury. In a...
BioCentury | Aug 11, 2020
Product Development

BIOEquality, data sharing and deals: a BioCentury podcast

BIO is calling on biopharmaceutical companies to put their pledges on social justice into practice as the trade group launches an initiative that aims to diversify the biotech workforce and ensure that...
BioCentury | Jul 31, 2020
Product Development

Can the vogue of decentralized trials continue beyond the pandemic?

...has been, the pandemic has made people more open to decentralized trials. According to one poll...
BioCentury | Jul 21, 2020
Product Development

Vaccine hopes, the shifting biopharma workplace & Blueprint’s Dx deal: a BioCentury Podcast

New data for the vaccine candidate from Oxford and AstraZeneca have stoked enthusiasm that countermeasures against COVID-19 are within reach. On the latest edition of the BioCentury This Week podcast , BioCentury editors discuss the latest...
BioCentury | Nov 1, 2019
Politics & Policy

Survey finds Europe top alternative for Chinese life science investors amid CFIUS concerns

A survey of Chinese investors revealed broad concern about U.S. restrictions on foreign investment in the life sciences that is diverting Chinese investments to other countries, with Europe cited as the top alternative for investment....
BioCentury | Sep 14, 2019

Mark Schoenebaum: Setting the gold standard Mark was already a biotech legend, well into his streak of consecutive Institutional Investor poll...
BioCentury | Aug 26, 2019
Financial News

RIP Mark Schoenebaum, treasured biopharma analyst

Mark Schoenebaum, an admired biopharma equity analyst, died over the weekend. Schoenebaum resigned as senior managing director and head of healthcare/biotech & pharma equity analyst at Evercore ISI in 2017. Prior to joining Evercore in...
BioCentury | Jul 13, 2018

Pause for politics

The near record-setting pace of 1H18 capital markets activity isn’t likely to be replicated this half, but that won’t be because of changes to sector fundamentals. Instead, it’s likely the consequence of macroeconomic and geopolitical...
Items per page:
1 - 10 of 229